Lady Gaga’s first fragrance to grace retail shelves in September
NEW YORK — Coty, in association with Lady Gaga’s Haus Labs, is releasing in September the artist’s first fragrance, called Lady Gaga Fame.
Lady Gaga Fame is the first-ever black Eau de Parfum that sprays clear and becomes invisible once airborne. The black-to-clear fragrance is an innovation of patent-pending fluid technology, exclusively launched with Lady Gaga Fame.
The innovations go beyond the black-to-clear fluid: The olfactory structure itself also is rare for the fragrance industry. Traditionally, perfumes have a pyramidal structure — a hierarchy of sorts with top, middle and base notes. This fragrance, on the other hand, has a unique structure called the "push-pull technology," where the ingredients interact together to highlight different olfactive aspects of each note at the same time, without any hierarchy.
The scent is built around three main accords: dark, sensual and light. The dark accord was inspired by belladonna, the deadly nightshade possessed by haunted beauties since the 18th century. From this darkness, the fragrance evolves to a fusion of dripping honey, saffron and apricot nectar. The rich floral layer of crushed tiger orchid and jasmine sambac embodies timeless beauty. The accords work together to create a fragrance of floral and fruity elements, with the star ingredient inspired by belladonna leveling out the whole fragrance and giving Lady Gaga Fame its signature as a scent.
Valeant to acquire OraPharma in $312 million deal
MONTREAL — Valeant Pharmaceuticals International has agreed to acquire a specialty oral health company that develops and commercializes products that improve and maintain oral health.
Valeant said it is acquiring OraPharma from private equity firm Water Street Healthcare Partners for $312 million. The drug maker also said it will pay $114 million in potential contingent payments based on certain milestones.
"We are excited to enter a new attractive market segment with an already established sales infrastructure focused entirely on the dental community," Valeant chairman and CEO J. Michael Pearson said. "We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese. We believe the OraPharma business is a new growth platform from which to build additional opportunities in the future."
FDA approves MenHibrix
PHILADELPHIA — GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.
MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine) is approved for use in children ages six weeks through 18 months. The vaccination schedule is a four-dose series given at two, four, six, and 12 through 15 months of age.
"All of us at GSK vaccines look at today’s approval as a good day for infants, toddlers and healthcare providers," said Leonard Friedland, VP and head of clinical and medical affairs of North America vaccine development for GSK Vaccines. "MenHibrix gives healthcare providers the option of combining Hib immunization with meningococcal C and Y immunization without increasing the number of shots for infants and toddlers."
In September 2011, the FDA declined to approve the drug and sent GSK a complete response letter.